360 related articles for article (PubMed ID: 7584502)
21. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
22. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.
Graziano RF; Fanger MW
J Immunol; 1987 Nov; 139(10):3536-41. PubMed ID: 2960735
[TBL] [Abstract][Full Text] [Related]
23. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
24. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
25. Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6.
Duits AJ; Aarden LA; Ernst LK; Capel PJ; van de Winkel JG
Clin Exp Immunol; 1993 May; 92(2):225-31. PubMed ID: 8485907
[TBL] [Abstract][Full Text] [Related]
26. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
[TBL] [Abstract][Full Text] [Related]
27. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
Parren PW; Warmerdam PA; Boeije LC; Arts J; Westerdaal NA; Vlug A; Capel PJ; Aarden LA; van de Winkel JG
J Clin Invest; 1992 Oct; 90(4):1537-46. PubMed ID: 1401085
[TBL] [Abstract][Full Text] [Related]
28. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
[TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
30. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
Chen X; Shen D; Sun T; Bai J; Huang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
[TBL] [Abstract][Full Text] [Related]
31. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
[TBL] [Abstract][Full Text] [Related]
32. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
33. T cell activation by anti-CD3 antibodies: function of Fc receptors on B cell blasts, but not resting B cells, and CD18 on the responding T cells.
Austyn JM; Smith KG; Morris PJ
Eur J Immunol; 1987 Sep; 17(9):1329-35. PubMed ID: 3498637
[TBL] [Abstract][Full Text] [Related]
34. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
35. Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.
Hattori K; Tsukamoto H; Ohta S; Yabe M; Yabe H; Kato S; Takakura I; Ueda R; Habu S; Nishimura T
Bone Marrow Transplant; 1995 Feb; 15(2):193-8. PubMed ID: 7773208
[TBL] [Abstract][Full Text] [Related]
36. Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes.
Van Den Herik-Oudijk IE; Westerdaal NA; Henriquez NV; Capel PJ; Van De Winkel JG
J Immunol; 1994 Jan; 152(2):574-85. PubMed ID: 8283039
[TBL] [Abstract][Full Text] [Related]
37. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the monocyte Fc receptors and antibody-mediated cellular interactions required for the induction of T cell proliferation by anti-T3 antibodies.
Clement LT; Tilden AB; Dunlap NE
J Immunol; 1985 Jul; 135(1):165-71. PubMed ID: 3923099
[TBL] [Abstract][Full Text] [Related]
39. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
40. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]